RU2461567C2 - Полипептид, способный блокировать рецептор клеточной поверхности ccr5 и/или вызывать интернализацию и/или подавляющую регуляцию ccr5 в клетке-мишени, кодирующая его нуклеиновая кислота, клетка-хозяин, применение (варианты), фармацевтическая композиция и способ лечения или профилактики вич-инфекции у пациента (варианты) - Google Patents

Полипептид, способный блокировать рецептор клеточной поверхности ccr5 и/или вызывать интернализацию и/или подавляющую регуляцию ccr5 в клетке-мишени, кодирующая его нуклеиновая кислота, клетка-хозяин, применение (варианты), фармацевтическая композиция и способ лечения или профилактики вич-инфекции у пациента (варианты) Download PDF

Info

Publication number
RU2461567C2
RU2461567C2 RU2009106436/10A RU2009106436A RU2461567C2 RU 2461567 C2 RU2461567 C2 RU 2461567C2 RU 2009106436/10 A RU2009106436/10 A RU 2009106436/10A RU 2009106436 A RU2009106436 A RU 2009106436A RU 2461567 C2 RU2461567 C2 RU 2461567C2
Authority
RU
Russia
Prior art keywords
ccr5
seq
hiv
polypeptide
agents
Prior art date
Application number
RU2009106436/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2009106436A (ru
Inventor
Оливер ХАРТЛИ (CH)
Оливер ХАРТЛИ
Original Assignee
Минтака Фаундэйшн Фор Медикал Рисерч,Сн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Минтака Фаундэйшн Фор Медикал Рисерч,Сн filed Critical Минтака Фаундэйшн Фор Медикал Рисерч,Сн
Publication of RU2009106436A publication Critical patent/RU2009106436A/ru
Application granted granted Critical
Publication of RU2461567C2 publication Critical patent/RU2461567C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
RU2009106436/10A 2006-07-25 2007-07-25 Полипептид, способный блокировать рецептор клеточной поверхности ccr5 и/или вызывать интернализацию и/или подавляющую регуляцию ccr5 в клетке-мишени, кодирующая его нуклеиновая кислота, клетка-хозяин, применение (варианты), фармацевтическая композиция и способ лечения или профилактики вич-инфекции у пациента (варианты) RU2461567C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
GB0614755.7 2006-07-25

Publications (2)

Publication Number Publication Date
RU2009106436A RU2009106436A (ru) 2010-08-27
RU2461567C2 true RU2461567C2 (ru) 2012-09-20

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009106436/10A RU2461567C2 (ru) 2006-07-25 2007-07-25 Полипептид, способный блокировать рецептор клеточной поверхности ccr5 и/или вызывать интернализацию и/или подавляющую регуляцию ccr5 в клетке-мишени, кодирующая его нуклеиновая кислота, клетка-хозяин, применение (варианты), фармацевтическая композиция и способ лечения или профилактики вич-инфекции у пациента (варианты)

Country Status (25)

Country Link
US (2) US8686111B2 (enExample)
EP (1) EP2076532B1 (enExample)
JP (1) JP5224603B2 (enExample)
KR (1) KR101530353B1 (enExample)
CN (1) CN101511867B (enExample)
AT (1) ATE490270T1 (enExample)
AU (1) AU2007278894B2 (enExample)
BR (1) BRPI0715331B8 (enExample)
CA (1) CA2658806C (enExample)
CY (1) CY1111630T1 (enExample)
DE (1) DE602007010969D1 (enExample)
DK (1) DK2076532T3 (enExample)
ES (1) ES2361455T3 (enExample)
GB (1) GB0614755D0 (enExample)
HR (1) HRP20110146T1 (enExample)
ME (1) ME01320B (enExample)
MX (1) MX2009000918A (enExample)
NZ (1) NZ575092A (enExample)
PL (1) PL2076532T3 (enExample)
PT (1) PT2076532E (enExample)
RS (1) RS51854B (enExample)
RU (1) RU2461567C2 (enExample)
SI (1) SI2076532T1 (enExample)
WO (1) WO2008012689A2 (enExample)
ZA (1) ZA200901342B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
AU2019276939A1 (en) 2018-05-28 2021-01-21 Orion Biotechnology Switzerland Sàrl CCR5 inhibitor for use in treating cancer
EP3813869B1 (en) * 2018-05-28 2023-10-18 Université de Genève Ccr5 inhibitor for use in treating a neuroinflammatory disorder that involves cerebral inflammation
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044462A1 (fr) * 1996-05-22 1997-11-27 Institut Pasteur Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
WO2003022884A2 (en) * 2001-09-05 2003-03-20 Universite Pierre Et Marie Curie (Paris Vi) Methods for construction and screening of libraries of chemokine variants
EP1316801B1 (en) * 2001-11-30 2005-11-23 ChemoCentryx Inc Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693098B2 (en) * 1993-06-09 1998-06-25 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044462A1 (fr) * 1996-05-22 1997-11-27 Institut Pasteur Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
WO2003022884A2 (en) * 2001-09-05 2003-03-20 Universite Pierre Et Marie Curie (Paris Vi) Methods for construction and screening of libraries of chemokine variants
EP1316801B1 (en) * 2001-11-30 2005-11-23 ChemoCentryx Inc Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

Also Published As

Publication number Publication date
ME01320B (me) 2013-12-20
US9328153B2 (en) 2016-05-03
BRPI0715331B8 (pt) 2021-05-25
WO2008012689A3 (en) 2008-05-08
SI2076532T1 (sl) 2011-06-30
EP2076532B1 (en) 2010-12-01
CA2658806C (en) 2017-01-03
ES2361455T3 (es) 2011-06-17
JP2009544304A (ja) 2009-12-17
CN101511867B (zh) 2014-04-09
RS51854B (sr) 2012-02-29
HK1131162A1 (en) 2010-01-15
PL2076532T3 (pl) 2011-07-29
KR20090060281A (ko) 2009-06-11
HRP20110146T1 (hr) 2011-06-30
NZ575092A (en) 2011-08-26
JP5224603B2 (ja) 2013-07-03
US20130330305A1 (en) 2013-12-12
WO2008012689A2 (en) 2008-01-31
US20090317363A1 (en) 2009-12-24
RU2009106436A (ru) 2010-08-27
CN101511867A (zh) 2009-08-19
DK2076532T3 (da) 2011-03-07
CA2658806A1 (en) 2008-01-31
ZA200901342B (en) 2010-11-24
GB0614755D0 (en) 2006-09-06
KR101530353B1 (ko) 2015-06-26
BRPI0715331B1 (pt) 2021-04-13
ATE490270T1 (de) 2010-12-15
MX2009000918A (es) 2009-08-26
CY1111630T1 (el) 2015-10-07
AU2007278894B2 (en) 2012-08-09
US8686111B2 (en) 2014-04-01
PT2076532E (pt) 2011-03-02
DE602007010969D1 (de) 2011-01-13
AU2007278894A1 (en) 2008-01-31
EP2076532A2 (en) 2009-07-08
BRPI0715331A2 (pt) 2013-07-16

Similar Documents

Publication Publication Date Title
US9328153B2 (en) Cytokine derivatives
US6168784B1 (en) N-terminal modifications of RANTES and methods of use
JP2001520673A (ja) 免疫不全ウイルス感染を阻害するケモカイン類およびそれに基づいた方法
WO2013131032A1 (en) Variants of prothymosin alpha and methods of using same
US20050164936A1 (en) Amino-terminally truncated rantes as chemokine antagonists
CN103025756B (zh) 凝集素及其用途
JP2004537964A (ja) インターフェロン、それに関する使用及び組成物
RU2290197C2 (ru) Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
AU3889600A (en) A novel chimeric protein for prevention and treatment of hiv infection
HK1131162B (en) Cytokine derivatives
TW200524625A (en) Antiviral compositions which inhibit paramyxovirus infection
KR101138930B1 (ko) Ｈⅰｖ ｎｃ 단백질을 포함하는 ａⅰｄｓ 예방 및 치료용조성물
JP7579880B2 (ja) 新型コロナウイルス感染の治療におけるＴＦＦ２タンパク質とＩＦＮ－κタンパク質の併用の応用
WO2024125271A1 (zh) 抗hiv-1的重组蛋白及其应用
CN117003852A (zh) 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20190517